IKT

Inhibikase Therapeutics Inc

IKT, USA

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

https://www.inhibikase.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IKT
stock
IKT

Inhibikase Therapeutics (IKT) Coverage Initiated by Cantor Fitzg GuruFocus

Read more →
IKT
stock
IKT

Reducing the human factor powertorque.com.au

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$8

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

1.90

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-16.37 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-14.99 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.09

Low 1

High 0.3

Investors

* Institutions hold a combined 80.76% of the total shares of Inhibikase Therapeutics Inc

1.

Sands Capital Ventures, LLC

(14.6947%)

since

2025/06/30

2.

Soleus Capital Management, L.P.

(8.488%)

since

2025/06/30

3.

Fairmount Funds Management LLC

(8.2196%)

since

2025/06/30

4.

Perceptive Advisors LLC

(7.29%)

since

2025/06/30

5.

COMMODORE CAPITAL LP

(7.2433%)

since

2025/06/30

6.

ADAR1 Capital Management LLC

(6.8738%)

since

2025/06/30

7.

Vanguard Group Inc

(4.327%)

since

2025/06/30

8.

BlackRock Inc

(3.6612%)

since

2025/06/30

9.

Blackstone Inc

(3.5405%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.9903%)

since

2025/07/31

11.

Nantahala Capital Management, LLC

(2.9389%)

since

2025/06/30

12.

Geode Capital Management, LLC

(1.4315%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(1.1088%)

since

2025/08/31

14.

Stonepine Capital Management Llc

(0.9847%)

since

2025/06/30

15.

Fidelity Small Cap Index

(0.8062%)

since

2025/06/30

16.

iShares Russell 2000 Value ETF

(0.6433%)

since

2025/08/31

17.

State Street Corp

(0.5339%)

since

2025/06/30

18.

Northern Trust Corp

(0.527%)

since

2025/06/30

19.

Susquehanna International Group, LLP

(0.5141%)

since

2025/06/30

20.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4605%)

since

2025/07/31

21.

Vanguard Russell 2000 ETF

(0.3903%)

since

2025/07/31

22.

State St Russell Sm Cap® Indx SL Cl I

(0.2841%)

since

2025/08/31

23.

Fidelity Extended Market Index

(0.2452%)

since

2025/07/31

24.

Blair William & Co

(0.2106%)

since

2025/06/30

25.

Charles Schwab Investment Management Inc

(0.2044%)

since

2025/06/30

26.

Schwab Small Cap Index

(0.2044%)

since

2025/07/31

27.

NT R2000 Index Fund - NL

(0.1963%)

since

2025/06/30

28.

FMR Inc

(0.1936%)

since

2025/06/30

29.

Fidelity Select Biotechnology

(0.1905%)

since

2025/07/31

30.

iShares Micro-Cap ETF

(0.1854%)

since

2025/08/31

31.

Bank of New York Mellon Corp

(0.1778%)

since

2025/06/30

32.

NT R2000 Index Fund - DC - NL - 3

(0.1565%)

since

2025/06/30

33.

Barclays PLC

(0.148%)

since

2025/06/30

34.

iShares Russell 2000 Small-Cap Idx Instl

(0.1406%)

since

2025/07/31

35.

Russell 2500™ Index Fund F

(0.1088%)

since

2025/06/30

36.

Nuveen Small Cap Blend Idx R6

(0.1056%)

since

2025/07/31

37.

Russell 2000 Index Non-Lendable Fund E

(0.0893%)

since

2025/06/30

38.

Fidelity Series Total Market Index

(0.0887%)

since

2025/07/31

39.

iShares Russell 2000 Growth ETF

(0.0857%)

since

2025/08/31

40.

EQ/2000 Managed Volatility IB

(0.0818%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.1325

EPS Estimate

-0.13

EPS Difference

-0.0025

Surprise Percent

-1.9231%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.